Pediatric Growth Hormone Deficiency Clinical Trial
Official title:
A Phase III, Randomized, Open-label, Positive-controlled, Multi-center Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency
A Phase III, Randomized, open-label, positive-drug parallel control, Study to Evaluate the Efficacy and Safety of TJ101 in Child subject with growth hormone deficieney.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01718041 -
Versartis Trial in Children to Assess Long-Acting Growth Hormone
|
Phase 1/Phase 2 | |
| Terminated |
NCT02068521 -
Versartis Long-Term Safety Study of Somavaratan
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05509894 -
Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
|
||
| Withdrawn |
NCT06113952 -
A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone
|
||
| Completed |
NCT01592500 -
Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
|
Phase 2 | |
| Active, not recruiting |
NCT02968004 -
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
|
Phase 3 | |
| Terminated |
NCT02413138 -
Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)
|
Phase 2/Phase 3 |